|Day Low/High||18.71 / 19.84|
|52 Wk Low/High||6.75 / 43.56|
There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.
They are raising cash, mitigating risk and staying patient.
Like Karuna, Sage Therapeutics and Intra-Cellular Therapies also deal in treatments in the mental health arena.
The rally has gained some strength since our last update as all the major indices have moved further in the black. However, we are seeing weakness in a lot of small biotech names as well as plenty of small E&P concerns despite the overall upward til...
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
Markets continue to be nicely in the black two hours into trading as resumption of U.S.-China trade talks have investors in a good mood to start off the second half of trading in 2019. Some small biotechs continue to show some strength this Monday. ...
The stock purchases by the insiders are at companies developing treatments for breast cancer and schizophrenia.
I continue to believe that biotech and biopharma stocks will outperform in 2018.
The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.
Shares of Intra-Cellular Therapies plummeted on Thursday as the biopharmaceutical company's phase three trial of its schizophrenia drug was unsuccessful.
Here are 4 stocks to take a look at as this hot-money action picks up.
If you miss the boat, consider a plan B, like buying on the open or looking for available weakness.